Profile data is unavailable for this security.
About the company
Eurocine Vaccines AB is a Sweden-based clinical-stage company, which develops nasal vaccines. The Company develops vaccines up to proof of concept (clinical phase I/II) and license to partners for further development and commercialization. Also, the Company offers license partners vaccine adjuvant technologies, which are a key element of the nasal vaccines, for development in various indications. For these purposes the Company’s uses its clinically validated technology Endocine. In addition, the Company’s primary project is the nasal quadrivalent influenza vaccine Immunos FLU that aims for children from six month. The Company cooperates with both academic researchers and contract businesses and owns all income generated in these collaborations.
- Revenue in SEK (TTM)5.00k
- Net income in SEK-15.06m
- Incorporated1999
- Employees3.00
- LocationEurocine Vaccines ABNanna Svartz vag 4SOLNA 171 65SwedenSWE
- Phone+46 850884592
- Fax+46 850884591
- Websitehttps://www.eurocine-vaccines.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XP Chemistries AB | 663.69k | -8.04m | 4.67m | 2.00 | -- | 0.1818 | -- | 7.04 | -0.2846 | -0.2846 | 0.0213 | 0.275 | 0.023 | 0.2084 | 5.99 | 331,845.00 | -27.79 | -- | -29.36 | -- | 50.57 | -- | -1,211.24 | -- | 5.79 | -- | 0.00 | -- | -37.14 | -- | -1.55 | -- | -- | -- |
| Eurocine Vaccines AB | 5.00k | -15.06m | 4.99m | 3.00 | -- | -- | -- | 997.93 | -0.1472 | -0.1472 | 0.00005 | -0.0018 | 0.0007 | -- | 0.002 | -- | -199.76 | -83.17 | -323.19 | -97.89 | -199,780.00 | -- | -301,180.00 | -- | -- | -- | -- | -- | -- | -- | 8.95 | -- | -- | -- |
| European Institute of Science AB | 600.00k | -2.72m | 5.77m | 0.00 | -- | 1.43 | -- | 9.62 | -4.25 | -4.25 | 0.9397 | 2.98 | 0.1728 | 0.8479 | 8.63 | -- | -78.21 | -93.04 | -82.77 | -103.14 | 62.33 | 67.01 | -452.67 | -518.82 | 10.54 | -- | -- | -- | 13.69 | 8.54 | 0.4062 | -- | -- | -- |
| QuiaPEG Pharmaceuticals Holding AB | 0.00 | -16.52m | 5.96m | 8.00 | -- | 0.3908 | -- | -- | -3.51 | -3.51 | 0.00 | 0.2047 | 0.00 | -- | -- | -- | -50.53 | -95.67 | -100.54 | -207.86 | -- | 262.59 | -- | -5,002.50 | -- | -15.34 | 0.00 | -- | -- | -- | 17.75 | -- | 47.06 | -- |
| Bio Vitos Pharma AB | 2.98m | -12.87m | 6.13m | 1.00 | -- | 1.59 | 11.95 | 2.06 | -0.2547 | -0.2547 | 0.0533 | 0.1119 | 0.0989 | 0.00 | 5.38 | 2,983,990.00 | -42.63 | -31.11 | -44.50 | -32.92 | 100.00 | -- | -431.21 | -1,026.76 | 4.27 | -- | 0.00 | -- | 126.97 | -- | 13.64 | -- | -- | -- |
| Lipidor AB | 77.00k | -11.49m | 6.69m | -- | -- | -- | -- | 86.93 | -0.3964 | -0.3964 | 0.0027 | -0.3223 | 0.0084 | -- | 5.31 | -- | -124.54 | -59.41 | -- | -75.10 | -- | -- | -14,916.88 | -643.36 | -- | -- | -- | -- | 73.33 | -20.33 | 72.24 | -- | -- | -- |
| 2cureX AB | 155.00k | -30.82m | 7.11m | -- | -- | 0.5195 | -- | 45.88 | -1.75 | -1.75 | 0.0088 | 0.7777 | 0.0048 | -- | 0.0838 | -- | -95.89 | -38.21 | -108.66 | -43.48 | -6,889.68 | -22,153.06 | -19,883.23 | -38,685.30 | -- | -46.08 | -- | -- | 72.22 | -- | -3.52 | -- | -- | -- |
| Stayble Therapeutics AB | 0.00 | -23.74m | 9.83m | 3.00 | -- | 0.5957 | -- | -- | -0.9492 | -0.9492 | 0.00 | 0.5204 | 0.00 | -- | -- | 0.00 | -116.21 | -78.64 | -141.76 | -95.58 | -- | -- | -- | -- | -- | -- | 0.049 | -- | -- | -- | 3.22 | -- | -- | -- |
| Amniotics AB (publ) | 0.00 | -30.87m | 10.66m | 6.00 | -- | 0.6803 | -- | -- | -0.0374 | -0.0374 | 0.00 | 0.0057 | 0.00 | -- | -- | 0.00 | -112.25 | -101.09 | -362.71 | -149.92 | -- | -- | -- | -- | 1.12 | -16.17 | -- | -- | -- | -- | 35.75 | -- | -- | -- |
| Carbiotix AB (publ) | 1.47m | -13.48m | 13.19m | 10.00 | -- | 0.1918 | -- | 9.00 | -0.302 | -0.302 | 0.0324 | 0.3817 | 0.0586 | -- | 2.36 | 146,552.00 | -53.88 | -49.38 | -64.85 | -55.50 | 235.45 | 574.69 | -919.76 | -1,828.86 | -- | -76.28 | 0.1384 | -- | 259.56 | -12.04 | -10.02 | -- | 13.64 | -- |
| Aptahem AB | 32.00k | -11.11m | 14.18m | -- | -- | 0.1386 | -- | 443.00 | -0.0497 | -0.0497 | 0.0001 | 0.2266 | 0.0005 | -- | 0.0738 | -- | -16.76 | -39.26 | -19.47 | -44.19 | 4,623.59 | -- | -34,727.72 | -- | -- | -10.17 | 0.0847 | -- | -- | -- | -25.36 | -- | -- | -- |
| AegirBio AB | 99.00k | -367.00m | 14.84m | 1.00 | -- | 1.66 | -- | 149.86 | -24.31 | -24.31 | 0.0047 | 0.2895 | 0.0004 | 2.00 | 0.0207 | -- | -163.02 | -- | -171.79 | -- | -24,398.99 | -- | -370,710.10 | -- | 2.53 | -27.27 | 0.8209 | -- | -87.16 | -- | -292.98 | -- | -- | -- |
| Redwood Pharma AB | 0.00 | -13.60m | 17.11m | 1.00 | -- | 0.2531 | -- | -- | -5.87 | -5.87 | 0.00 | 3.18 | 0.00 | -- | -- | 0.00 | -106.53 | -95.03 | -121.24 | -123.04 | -- | -- | -- | -- | -- | -19.12 | 0.00 | -- | -- | -- | -8.78 | -- | -5.11 | -- |
Data as of May 03 2024. Currency figures normalised to Eurocine Vaccines AB's reporting currency: Swedish Krona SEK
